Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jeremy Hofer"'
Autor:
Sachin P. Patil, Elena Fattakhova, Jeremy Hofer, Michael Oravic, Autumn Bender, Jason Brearey, Daniel Parker, Madison Radnoff, Zackary Smith
Publikováno v:
Pharmaceuticals, Vol 15, Iss 5, p 613 (2022)
The selective activation of the innate immune system through blockade of immune checkpoint PD1-PDL1 interaction has proven effective against a variety of cancers. In contrast to six antibody therapies approved and several under clinical investigation
Externí odkaz:
https://doaj.org/article/b22a3f01d1e441d484a22c77e0d183c3
Autor:
Michelle DiFrancesco, Jeremy Hofer, Abhay Aradhya, Jeffrey Rufinus, John Stoddart, Stephen Finocchiaro, Jabari Mani, Sean Tevis, Michael Visconti, Griffin Walawender, Juliette DiFlumeri, Elena Fattakhova, Sachin P. Patil
Publikováno v:
Computational biology and chemistry. 102
Inhibition of the interaction between the PD-1 protein on activated lymphocytes and the PD-L1 protein on tumors represents a novel therapeutic approach for selective activation of the innate immune response against a variety of cancers. Therefore, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08da4b6e114b7a5b9427168081883840
https://pubmed.ncbi.nlm.nih.gov/36610303
https://pubmed.ncbi.nlm.nih.gov/36610303
Autor:
Madison Cobb, Jeremy Hofer, Justin Wellington, Michael Oravic, Madison Radnoff, Elena Fattakhova, Timothy Dando, Juliette DiFlumeri, Sachin P. Patil, Zachary Romisher
Publikováno v:
ChemMedChem. 16(18)
Immune checkpoint blockade involving inhibition of the PD-1/PD-L1 interaction has provided unprecedented clinical benefits in treating a variety of tumors. To date, a total of six antibodies that bind to either PD-1 or PD-L1 protein and in turn inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64448c43bd996f3b552b94a74a8dae67
https://pubmed.ncbi.nlm.nih.gov/34117723
https://pubmed.ncbi.nlm.nih.gov/34117723
Autor:
E. Fattakhova, Oravic M, Dando T, J. Diflumeri, Romisher Z, Wellington J, Sachin P. Patil, Jeremy Hofer, Cobb M, Radnoff M
Immune checkpoint blockade involving inhibition of the PD-1/PD-L1 interaction has provided unprecedented clinical benefits in treating a variety of tumors. To date, a total of six antibodies that bind to either PD-1 or PD-L1 protein and in turn inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0973aa4307a82573d8507ba66dc74d92
https://doi.org/10.26434/chemrxiv.14438861.v1
https://doi.org/10.26434/chemrxiv.14438861.v1
Autor:
Sachin Patil, Madison Radnoff, Michael Oravic, Justin Wellington, Zachary Romisher, Timothy Dando, Madison Cobb, Juliette DiFlumeri, Jeremy Hofer, Elena Fattakhova
Immune checkpoint blockade involving inhibition of the PD-1/PD-L1 interaction has provided unprecedented clinical benefits in treating a variety of tumors. To date, a total of six antibodies that bind to either PD-1 or PD-L1 protein and in turn inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3356c64c13cfb1a55571de2222e5c8b7
https://doi.org/10.26434/chemrxiv.14438861
https://doi.org/10.26434/chemrxiv.14438861
Autor:
Michael Oravic, Autumn Campbell, Juliette DiFlumeri, Elena Fattakhova, Pedro J. Ballester, Jeremy Hofer, Sachin Patil
Objective There is an increased interest in drug repurposing against Covid-19 (SARS-CoV-2) as its spread has significantly outpaced development of effective therapeutics. Our aim is to identify approved drugs that can inhibit the interaction of SARS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c554489c5f8c93946918db09957e9e7
https://doi.org/10.26434/chemrxiv.12482435
https://doi.org/10.26434/chemrxiv.12482435
Autor:
Marie C. Herb, James E. Fisher, Suk-Chung Yoon, Sachin P. Patil, Madison A. Fink, Erika S. Enley, Jeremy Hofer, Anthony Klingos, Megan T. Fedorky, Abhay G. Aradhya, James T. Proulx
Publikováno v:
Chemicalpharmaceutical bulletin. 66(8)
The ability of tumors to escape from immune destruction is attributed to the protein-protein interaction between programmed cell death protein 1 (PD1) and programmed cell death ligand 1 (PDL1) proteins expressed by immune T cells and cancer cells, re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c772f01190d9bfca7463607b846eebd8
https://pubmed.ncbi.nlm.nih.gov/30068796
https://pubmed.ncbi.nlm.nih.gov/30068796